NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs

Journal of Clinical Investigation

Volumn 115, Issue 11, 2005, Pages 3093-3103

  Morris, Edward S ^a,b   MacDonald, Kelli P A ^a   Rowe, Vanessa ^a   Banovic, Tatjana ^a   Kuns, Rachel D ^a   Don, Alistair L J ^a   Bofinger, Helen M ^a   Burman, Angela C ^a   Olver, Stuart D ^a   Kienzle, Norbert ^a   Porcelli, Steven A ^c   Pellicci, Daniel G ^d   Godfrey, Dale I ^d   Smyth, Mark J ^e   Hill, Geoffrey R ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD8 ANTIGEN; CHIMERIC PROTEIN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR; PERFORIN; PROGENIPOIETIN 1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG POTENCY; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOREGULATION; LEUKEMIA; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLONY-STIMULATING FACTORS; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; KILLER CELLS, NATURAL; LEUKEMIA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 27644443729     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25249     Document Type: Article

References (83)

1. Godfrey, D.I., MacDonald, H.R., Kronenberg, M., Smyth, M.J., and Van Kaer, L. 2004. NKT cells: what's in a name? Nat. Rev. Immunol. 4:231-237.
2. Godfrey, D.I., Hammond, K.J., Poulton, L.D., Smyth, M.J., and Baxter, A.G. 2000. NKT cells: facts, functions and fallacies. Immunol. Today. 21:573-583.
3. Gumperz, J.E. 2004. Antigen specificity of semi-invariant CD1d-restricted T cell receptors: the best of both worlds? Immunol. Cell Biol. 82:285-294.
4. Crowe, N.Y., et al. 2003. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J. Immunol. 171:4020-4027.
5. Higuchi, M., et al. 2002. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. J. Immunol. 169:5564-5570.
6. Zeng, D., et al. 1999. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J. Exp. Med. 189:1073-1081.
7. Lan, F., Zeng, D., Higuchi, M., Higgins, J.P., and Strober, S. 2003. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol. Blood Marrow Transplant. 9:355-363.
8. Seino, K.I., et al. 2001. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. U. S. A. 98:2577-2581.
9. Smyth, M.J., et al. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:661-668.
10. Crowe, N.Y., Smyth, M.J., and Godfrey, D.I. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119-127.
11. Gillessen, S., et al. 2003. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc. Natl. Acad. Sci. U. S. A. 100:8874-8879.
12. Terabe, M., et al. 2003. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741-1752.
13. Smyth, M.J., et al. 2002. NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 14:165-171.
14. Cashen, A.F., Link, D., Devine, S., and Dipersio, J. 2004. Cytokines and stem cell mobilization for autologous and allogeneic transplantation. Curr. Hematol. Rep. 3:406-412.
15. Pan, L., et al. 1999. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood. 93:4071-4078.
16. Krijanovski, O.I., et al. 1999. Keratinocyte growth factor (KGF) separates graft-versus-leukemia effects from graft-versus-host disease. Blood. 94:825-831.
17. Teshima, T., et al 1999. Interleukin-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J. Clin. Invest. 104:317-325.
18. Hill, G.R., et al. 1999. Differential roles of IL-1 and TNFa on graft-versus-host disease and graft versus leukemia. J. Clin. Invest. 104:459-467.
19. Reddy, P., et al. 2003. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 101:2877-2885.
20. Sykes, M., Abraham, V.S., Harry, M.W., and Pearson, D.A. 1993. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J. Immunol. 150:197-205.
21. Yang, Y., et al. 1997. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 90:4651-4660.
22. Yang, Y.G., Qi, J., Wang, M.G., and Sykes, M. 2002. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood. 99:4207-4215.
23. Morris, E.S., et al. 2004. Donor treatment with pegylated G-CSF augments the generation of IL-10 producing regulatory T cells and promotes transplant tolerance. Blood. 103:3573-3581.
24. Horowitz, M.M., et al. 1990. Graft-verus-leukemia reactions after bone marrow transplantation. Blood. 75:555-562.
25. Jones, S.C., Murphy, G.F., and Korngold, R. 2003. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol. Blood Marrow Transplant. 9:243-256.
26. Edinger, M., et al. 2003. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9:1144-1150.
27. Streeter, P.R., et al. 2001. Progenipoietins: biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony- stimulating factor receptor. Exp. Hematol. 29:41-50.
28. Fleming, W.H., Mulcahy, J.M., McKearn, J.P., and Streeter, P.R. 2001. Progenipoietin-1: a multifunctional agonist of the granulocyte colony-stimulating factor receptor and fetal liver tyrosine kinase-3 is a potent mobilizer of hematopoietic stem cells. Exp. Hematol. 29:943-951.
29. Pullarkat, V., et al. 2003. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastacic melanoma. Clin. Cancer Res. 9:1301-1312.
30. MacDonald, K.P., et al. 2003. Donor pretreatment wich progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood. 101:2033-2042.
31. Baker, J., Verneris, M.R., Ito, M., Shizuru, J.A., and Negrin, R.S. 2001. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 97:2923-2931.
32. Kawamura, H., et al. 1999. Expansion of extrathymic T cells as well as granulocytes in the liver and other organs of granulocyte-colony stimulating factor transgenic mice: why they lost the ability of hybrid resistance. J. Immunol. 162:5957-5964.
33. Wilson, S.B., and Delovitch, T.L. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3:211-222.
34. Cui, J., et al. 1997. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 278:1623-1626.
35. Mapara, M.Y., et al. 2002. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 100:1903-1909.
36. Nestel, F.P., Price, K.S., Seemayer, T.A., and Lapp, W.S. 1992. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 175:405-413.
37. MacDonald, K.P., et al. 2005. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J. Immunol. 174:1841-1850.
38. Schmaltz, C., et al. 2002. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8:1433-1437.
39. Pan, L., Delmonte, J., Jalonen, C.K., and Ferrara, J.L.M. 1995. Pretreatment of donors with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type 2 cytokine production and reduces severity of experimental graft versus host disease. Blood 86:4422-4429.
40. Vigorito, A.C., et al. 1998. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 22:1145-1151.
41. Schmitz, N., et al. 1998. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 21:995-1003.
42. Blaise, D., et al. 2000. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J. Clin. Oncol. 18:537-546.
43. Powles, R., et al. 2000. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 355:1231-1237.
44. Bensinger, W.I., et al. 2001. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N. Engl. J. Med. 344:175-181.
45. Oehler, V.G., et al. 2005. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol. Blood Marrow Transplant. 11:85-92.
46. Rutella, S., et al. 2002. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood. 100:2562-2571.
47. Egi, H., Hayamizu, K., Ohmori, I., Kitayama, T., and Asahara, T. 2002. Upregulation of intragraft interleukin-10 by infusion of granulocyte colony-stimulating factor-mobilized donor leukocytes. Transpl. Int. 15:479-485.
48. Husmann, L.A., and Bevan, M.J. 1988. Cooperation between helper T cells and cytotoxic T lymphocyte precursors. Ann. N. Y. Acad. Sci. 532:158-169.
49. Smyth, M.J., et al. 2002. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood. 99:1259-1266.
50. Stewart, T.J., Smyth, M.J., Fernando, G.J., Frazer, I.H., and Leggatt, G.R. 2003. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res. 63:3058-3060.
51. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., and Steinman, R.M. 2003. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267-279.
52. Denkers, E.Y., Scharton-Ketsten, T., Barbieri, S., Caspar, P., and Sher, A. 1996. A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection. J. Exp. Med. 184:131-139.
53. Johnson, T.R., Hong, S., Van Kaer, L., Koezuka, Y., and Graham, S.S. 2002. NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J. Virol. 76:4294-4303.
54. Stober, D., Jomantaite, I., Schirmbeck, R., and Reimann, J. 2003. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J. Immunol. 170:2540-2548.
55. Behar, S.M., Podrebarac, T.A., Roy, C.J., Wang, C.R., and Brenner, M.B. 1999. Diverse TCRs recognize murine CD1. J. Immunol. 162:161-167.
56. Morecki, S., et al. 2004. Effect of KRN7000 on induced graft-vs.-host disease. Exp. Hematol. 32:630-637.
57. Hashimoto, D., et al. 2005. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol. 174:551-556.
58. Shlomchik, W.D., et al. 1999. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 285:412-415.
59. Matte, C.C., et al. 2004. Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10:987-992.
60. Honda, S., et al. 1997. Expansion of an unusual population of Gr-1+CD3int cells in the lymph nodes and other peripheral organs of mice carrying the lpr gene. Cell Immunol. 177:144-153.
61. Yanagisawa, K., et al. 2002. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J. Immunol. 168:6494-6499.
62. Tanaka, J., et al. 2004. Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood. 104:768-774.
63. +NKT cells. J. Immunol. 173:4960-4966.
64. Haraguchi, K., et al. 2004. Recovery of Valpha24(+) NKT cells after hematopoietic stem cell transplantation. Bone Marrow Transplant. 34:595-602.
65. Leite-De-Moraes, M.C., et al. 1998. IL-4-producing NKT cells are biased towards IFN-gamma production by IL-12. Influence of the microenvironment on the functional capacities of NK T cells. Eur. J. Immunol. 28:1507-1515.
66. Leite-De-Moraes, M.C., et al. 2001. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J. Immunol. 166:945-951.
67. Leite-De-Moraes, M.C., et al. 1999. A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement. J. Immunol. 163:5871-5876.
68. Taylor, P.A., Lees, C.J., and Blazar, B.R. 2002. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 99:3493-3499.
69. Hoffmann, P., Ermann, J., Edinger, M., Fathman, C.G., and Strober, S. 2002. Donor-type CD4(+)CD2S(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196:389-399.
70. Cohen, J.L., Trenado, A., Vasey, D., Klatzmann, D., and Salomon, B.L. 2002. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196:401-406.
71. Cretney, E., et al. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168:1356-1361.
72. Yu, K.O., et al. 2005. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc. Natl. Acad. Sci. U. S. A. 102:3383-3388.
73. Hill, G.R., et al. 1997. Total body irradiation and acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood. 90:3204-3213.
74. Hill, G.R., et al. 1998. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102:115-123.
75. Cooke, K.R., et al. 2000. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation. 70:272-279.
76. Contag, P.R., Olomu, I.N., Stevenson, D.K., and Contag, C.H. 1998. Bioluminescent indicators in living mammals. Nat. Med. 4:245-247.
77. Reddy, P., et al. 2001. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194:1433-1440.
78. Schmaltz, C., et al. 2001. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood. 97:2886-2895.
79. Kienzle, N., Olver, S., Buttigieg, K., and Kelso, A. 2002. The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers. J. Immunol. Methods. 267:99-108.
80. Vremec, D., Pooley, J., Hochrein, H., Wu, L., and Shottman, K. 2000. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164:2978-2986.
81. Lipford, G.B., Bendigs, S., Heeg, K., and Wagner, H. 2000. Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. Immunology. 101:46-52.
82. Matsuda, J.L., et al. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741-754.
83. Hammond, K.J., et al. 2001. CD1d-restricted NKT cells: an interstrain comparison. J. Immunol. 167:1164-1173.